Antidepressant drugs may not be best treatment: Robert Whitaker
Research shows SSRIs reduce brain’s capacity to produce serotonin
For the past 25 years, people suffering from depression have been treated with antidepressant drugs like Zoloft, Prozac and Paxil — three of the world’s best-selling selective serotonin reuptake inhibitors, or SSRIs. But people are questioning whether these drugs are the appropriate treatment for depression, and if they could even be causing harm.
The drugs are designed to address a chemical imbalance in the brain and thereby relieve the symptoms of depression. In this case, it’s a shortage of serotonin that antidepressants work to correct.
In fact, there are pharmaceutical treatments targeting chemical imbalances for just about every form of mental illness, from schizophrenia to ADHD, and a raft of anxiety disorders. Hundreds of millions of prescriptions are written for antipsychotic, antidepressant and anti-anxiety medications every year in the United States alone, producing billions of dollars in revenue for pharmaceutical companies.
But what if the very premise behind these drugs is flawed? What if mental illnesses like depression aren’t really caused by chemical imbalances, and that millions of the people who are prescribed those drugs derive no benefit from them? And what if those drugs could actually make their mental illness worse and more intractable over the long term?
Investigative journalist Robert Whitaker argued that psychiatric drugs are a largely ineffective way of treating mental illness in his 2010 book called Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs and the Astonishing Rise of Mental Illness in America.
Whitaker maintains that the foundation of modern psychiatry, the chemical imbalance model, is scientifically unproven.
“If you dig into the science behind it,” Whitaker told Michael Enright, host of The Sunday Edition on CBC Radio, “you’ll find out that it’s not true, and that this was a hypothesis that arose in the 1960s, that depression was due to low serotonin, and that it was investigated and found not to be true by the early 1980s. And there was subsequent research to see if this was so, and it never panned out.
The Sunday Edition
On CBC radio's The Sunday Edition starting at 9 a.m. June 8:
The pursuit of poetry: Michael Enright on how poetry can come at you at just the wrong time.
Female fighter pilots: 25 years ago this week, the Canadian Air Force introduced the country to its first female fighter pilots.
Her Excellency Sharon Johnston: She is more than the wife of Canada's Governor-General. She's a rehabilitation scientist, a committed volunteer, the mother of five, the former manager of a horse boarding business and an author.
House of Dreams: The story of three mothers, determined to secure a future for their profoundly disabled adult sons.
Corporate tax evasion: The OECD thinks it has found a way to get the most powerful corporations on the planet to pay their fair share of taxes. A conversation with French economist Pascal Saint-Amans.
Carved in Stone: Alisa Siegel shares the story of Eleanor Milne, Canada's first Dominion Sculptor, who took a younger lawyer-turned-carver under her wing, and gave her the most precious gift of all.
Moving back home: Almost half of Canadians in their twenties now live with their parents. Brett Throop, tells his story in an essay called "A Year of Practical Living."
“And as early as 1998, the American Psychiatric Association in its textbook says we’re not finding that people with depression have any abnormality in their serotonin, but because it’s such an effective metaphor for getting people to take the drugs and sell the drugs, it’s continued to be promoted.”
Whitaker’s book was unsurprisingly controversial upon its release, but it went on to win the 2010 Investigative Reporters and Editors Book Award. And since its publication, an increasing number of influential psychiatric researchers have publicly come around to Whitaker's point of view.
In fact, Ronald Pies, a psychiatrist and the former editor of The Psychiatric Times, refers to the chemical imbalance hypothesis as an “urban legend” that well-informed psychiatrists never bought into.
Whitaker says that when Anatomy of an Epidemic came out, the controversy wasn’t so much over his debunking of the chemical imbalance hypothesis. It was over his finding that people who took psychiatric drugs were more likely to exhibit symptoms five years after being diagnosed than those who did not take the drugs.
But Thomas Insel, the director of the National Institute of Mental Health in the U.S., has weighed in on antipsychotic drugs, used to treat mental illnesses like schizophrenia, and reached a conclusion that echoes Whitaker’s.
According to Whitaker, research suggests that while people suffering from depression may not have low serotonin levels to begin with, the use of SSRIs reduces the brain’s capacity to produce serotonin on its own, leading to a worsening of symptoms when patients stop taking the drugs.
“One of the worries,” said Whitaker, “is that if you’re on these medications long enough, when you come off, will your brain re-normalize? And that’s an open question now.
“What is quite clear is that the drug alone rarely leads to long-term recovery.”
[You can listen to Michael Enright’s full interview with Robert Whitaker this weekend on The Sunday Edition, just after the 9 a.m. news on CBC Radio One, or in the player at the top-left of this story.]
To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.
By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.
Become a CBC Account Holder
Join the conversation Create account
Already have an account?